What is the share price of Vanta Bioscience Ltd (VANTABIO) today?
The share price of VANTABIO as on 4th December 2025 is ₹21.45. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Vanta Bioscience Ltd (VANTABIO) share?
The past returns of Vanta Bioscience Ltd (VANTABIO) share are- Past 1 week: -4.73%
- Past 1 month: -9.51%
- Past 3 months: -2.63%
- Past 6 months: -18.38%
- Past 1 year: -55.14%
- Past 3 years: -73.19%
- Past 5 years: -84.68%
What are the peers or stocks similar to Vanta Bioscience Ltd (VANTABIO)?
The peers or stocks similar to Vanta Bioscience Ltd (VANTABIO) include:What is the market cap of Vanta Bioscience Ltd (VANTABIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vanta Bioscience Ltd (VANTABIO) is ₹15.26 Cr as of 4th December 2025.What is the 52 week high and low of Vanta Bioscience Ltd (VANTABIO) share?
The 52-week high of Vanta Bioscience Ltd (VANTABIO) is ₹49.86 and the 52-week low is ₹19.08.What is the PE and PB ratio of Vanta Bioscience Ltd (VANTABIO) stock?
The P/E (price-to-earnings) ratio of Vanta Bioscience Ltd (VANTABIO) is -3.19. The P/B (price-to-book) ratio is 4.04.Which sector does Vanta Bioscience Ltd (VANTABIO) belong to?
Vanta Bioscience Ltd (VANTABIO) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.How to buy Vanta Bioscience Ltd (VANTABIO) shares?
You can directly buy Vanta Bioscience Ltd (VANTABIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Vanta Bioscience Ltd
VANTABIO Share Price
21.450.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VANTABIO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
VANTABIO Performance & Key Metrics
VANTABIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 4.04 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
VANTABIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VANTABIO Company Profile
The company is a preclinical contract research company. It provides preclinical safety assessment services, assessment services for evaluating the safety of the active pharmaceutical ingredients (API), etc.
DIVISLAB
PE Ratio
78.38
78.38
1Y Return
3.40%
3.40%
Buy Reco %
54.17
54.17
SYNGENE
PE Ratio
52.00
52.00
1Y Return
30.79%
30.79%
Buy Reco %
83.33
83.33
AARTIPHARM
PE Ratio
24.08
24.08
1Y Return
10.47%
10.47%
Buy Reco %
0.00
0.00
PE Ratio
1,106.00
1,106.00
1Y Return
12.02%
12.02%
Buy Reco %
0.00
0.00
VIMTALABS
PE Ratio
40.30
40.30
1Y Return
29.79%
29.79%
Buy Reco %
0.00
0.00
VANTABIO Forecast
VANTABIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VANTABIO
VANTABIO
Income
Balance Sheet
Cash Flow
Annual Normal View
VANTABIO Income Statement
VANTABIO Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.04 | 12.65 | 14.25 | 10.07 | 10.11 | 6.97 | 9.83 | 2.07 | — | |||||||||
Raw Materials | 2.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||||
| Power & Fuel Cost | 0.98 | 1.04 | 0.54 | 0.55 | 0.75 | 1.01 | 0.43 | |||||||||||
| Employee Cost | 2.90 | 3.93 | 2.51 | 2.67 | 3.46 | 3.79 | 1.76 | |||||||||||
| Selling & Administrative Expenses | 3.23 | 3.30 | 1.94 | 2.00 | 3.08 | 2.53 | 2.26 | |||||||||||
| Operating & Other expenses | 2.04 | 1.50 | 1.10 | 1.00 | 1.38 | 1.08 | 1.77 | |||||||||||
EBITDA | 1.08 | 3.50 | 4.48 | 3.98 | 3.89 | -1.70 | 1.42 | -4.15 | — | |||||||||
| Depreciation/Amortization | 0.57 | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.42 | — | |||||||||
| PBIT | 0.51 | 2.79 | 3.29 | 2.73 | 2.57 | -4.37 | -3.08 | -8.57 | — | |||||||||
| Interest & Other Items | 0.20 | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 4.07 | — | |||||||||
| PBT | 0.31 | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -12.64 | — | |||||||||
| Taxes & Other Items | 0.29 | 0.40 | 0.34 | 0.14 | 0.14 | -3.78 | -6.51 | -7.86 | — | |||||||||
| Net Income | 0.02 | 0.70 | 1.00 | 0.45 | 0.08 | -6.48 | -2.32 | -4.78 | — | |||||||||
| EPS | 0.05 | 1.11 | 1.58 | 0.71 | 0.13 | -10.27 | -3.68 | -7.57 | — | |||||||||
| DPS | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
VANTABIO Company Updates
VANTABIO Stock Peers
VANTABIO Past Performance & Peer Comparison
VANTABIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareLabs & Life Sciences Services
Compare valuation on Screener
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Vanta Bioscience Ltd | -3.19 | 4.04 | — |
| Divi's Laboratories Ltd | 78.38 | 11.47 | 0.46% |
| Syngene International Ltd | 52.00 | 5.46 | 0.19% |
| Aarti Pharmalabs Ltd | 24.08 | 3.30 | 0.69% |
VANTABIO Stock Price Comparison
Compare VANTABIO with any stock or ETFCompare VANTABIO with any stock or ETF
VANTABIO
VANTABIO Holdings
VANTABIO Shareholdings
VANTABIO Promoter Holdings Trend
VANTABIO Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 3.45%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VANTABIO Institutional Holdings Trend
VANTABIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VANTABIO Shareholding Pattern
VANTABIO Shareholding Pattern
VANTABIO Shareholding History
VANTABIO Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VANTABIO stock
smallcases containing VANTABIO stock
Looks like this stock is not in any smallcase yet.
VANTABIO Events
VANTABIO Events
VANTABIO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VANTABIO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VANTABIO Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
VANTABIO has not given any dividends in last 5 years
VANTABIO Dividends
VANTABIO Dividends
Hmm, looks like data is unavailable here. Please come back after some timeVANTABIO Stock News & Opinions
VANTABIO Stock News & Opinions
Articles & Videos
Corporate
Vanta Bioscience to discuss results
Vanta Bioscience will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Vanta Bioscience to conduct AGM
Vanta Bioscience announced that the 9th Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Vanta Bioscience revises board meeting date
Vanta Bioscience has revised the meeting of the Board of Directors which was scheduled to be held on 29 July 2025. The meeting will now be held on 1 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Vanta Bioscience revises board meeting date
Vanta Bioscience has revised the meeting of the Board of Directors which was scheduled to be held on 24 July 2025. The meeting will now be held on 29 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Vanta Bioscience revises board meeting date
Vanta Bioscience has revised the meeting of the Board of Directors which was scheduled to be held on 19 July 2025. The meeting will now be held on 24 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Vanta Bioscience schedules board meeting
Vanta Bioscience will hold a meeting of the Board of Directors of the Company on 19 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Vanta Bioscience cancels board meeting
Vanta Bioscience has cancelled the board meeting which was scheduled to be held on 30 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Vanta Bioscience schedules board meeting
Vanta Bioscience will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Vanta Bioscience schedules EGM
Vanta Bioscience announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 January 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Vanta Bioscience to hold board meeting
Vanta Bioscience will hold a meeting of the Board of Directors of the Company on 6 December 2024Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -32.01%, vs industry avg of 7.49%
Over the last 5 years, market share decreased from 0.12% to 0.01%